Carcinoma  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00574483: Treatment of Advanced Renal Cell Carcinoma With Quinacrine

Withdrawn
2
0
US
quinacrine, CBLC102
Cleveland BioLabs
Renal Cell Carcinoma
01/08
01/08
NCT00494091: Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

Checkmark P2 data
Jul 2012 - Jul 2012: P2 data
Completed
2
82
Japan, RoW
Temsirolimus (CCI-779), Torisel
Pfizer
Advanced Renal Cell Carcinoma
05/11
03/12
NCT01009203: Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Checkmark Torisel+Tarceva
Feb 2013 - Feb 2013: Torisel+Tarceva
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Terminated
2
13
US
Erlotinib, Tarceva, OSI-774, Temsirolimus, Torisel, CCI-779
New Mexico Cancer Care Alliance, Genentech, Inc.
Squamous Cell Carcinoma
09/12
12/12
NCT00782275: Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
41
US
bevacizumab, avastin, temsirolimus, torisel
Beth Israel Deaconess Medical Center, Genentech, Inc., Dana-Farber Cancer Institute, Brigham and Women's Hospital, Vanderbilt University Medical Center
Renal Cell Carcinoma, Kidney Cancer
05/15
05/15
PUMA-NER-4201, NCT01827267 / 2012-004743-68: Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Checkmark From HER2 mutant NSCLC
Sep 2014 - Sep 2014: From HER2 mutant NSCLC
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
62
US, Europe
neratinib, Nerlynx, temsirolimus, Torisel
Puma Biotechnology, Inc.
HER2-mutant Non-Small Cell Lung Cancer
09/16
10/17
NCT00106353: Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Completed
1/2
71
US, Canada, Europe, RoW
Torisel, temsirolimus
Pfizer
Adenocarcinoma, Neoplasms
10/09
01/12

Download Options